Ernesto Guccione | Mount Sinai

About Me

During my PhD at the International Center for Genetic Engineering Biotechnology (ICGEB) I have studied the oncogenic functions of HPV E6/E7 viral proteins and the relevance of splicing in regulating E6 functions. My postdoctoral work at the European Institute of Oncology I studied the role of chromatin in defining c-MYC target site recognition. I have also identified PRMT6, a member of the Protein Arginine MethylTransferase (PRMT) family, as an important enzyme regulating transcriptional repression.

In 2008 I started my lab at A*STAR in Singapore where I was promoted to Research Director and Coordinated the program of Epigenetics and Diseases.

In 2019 I moved to the department of Oncological Sciences and Pharmacological Sciences at Icahn School of Medicine at Mount Sinai where I am currently an Associate Professor.

My lab has a long-standing interest in understanding basic mechanisms of transcriptional and post-transcriptional regulation in order to identify therapeutic opportunities in oncology.

Currently, we are interested in the function in development and disease of Protein MethylTrasnferases (PMTs) and in modulation of Alternative Splicing using Splice switching Antisense Oligonucleotide (AON)-based approaches.

Lab Website: Guccione Lab

Language

English

Position

PROFESSOR | Oncological Sciences, PROFESSOR | Pharmacological Sciences, PROFESSOR | Immunology & Immunotherapy

Research Topics

Cancer, Developmental Biology, Epigenetics, Post-Transcriptional Processing

Multi-Disciplinary Training Areas

Cancer Biology [CAB], Development Regeneration and Stem Cells [DRS]

Education

MS, University of Bologna

PhD, International School for Advanced Studies (SISSA)/International Center for Genetic Engineering Biotechnology (ICGEB)

Post Doc, European Institute of Oncology

Research

The Guccione lab has a long-standing interest in understanding basic mechanisms of transcriptional and post-transcriptional regulation in order to identify therapeutic opportunities in oncology. Currently, we are interested in the function in development and disease of Protein MethylTrasnferases (PMTs) and in modulation of Alternative Splicing using Antisense Oligonucleotide (AON)-based approaches. We use biochemistry, mouse models and next generation sequencing techniques to understand the molecular mechanisms of action of candidate PMTs or specific isoforms. The range of techniques and approaches used in the lab has allowed us to characterize the mechanism of action of specific PMTs (e.g. PRMT5 and PRMT6) or oncogenic isoforms (e.g. MDM4l/s), which are now of great interest for their clinical applications.